[1] 艾玛,王环君,欧阳俊.新型抗凝剂对糖尿病房颤患者中风的预防作用[J].糖尿病天地:临床,2013,7(8):372~375. [2] Xiong Q, Lau YC,Senoo K,et al. Non‐vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta‐analysis of randomized trial[J].Eurpean Journal of Heart Failure, 2016,17(11):1192~1200. [3] Sameer B,Zachary B,Jonathan LH,et al. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation:the rivaroxaban once-daily, oral, direct factor xaInhibition compared with vitamin K antagonismfor prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF Trial)[J].American Heart Journal. 2015,170 (4):675~682. [4] Justin AE, Basil SL, Renato DL,et al. Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial[J].European Heart Journal Cardiovascular Pharmacotherapy,2015,1(2):86~94. [5] Michela B,Harald D,Jonas O,et al. Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial[J].International Journal of Cardiology,2015,196:127~131. [6] 陈建康,朱鹏立,严瑜,等. 小剂量利伐沙班对预防2型糖尿病伴心房颤动高龄患者脑卒中的疗效分析[J].中国医科大学学报,44(8):755~757. [7] 张琳,杨秋萍,吴亚楠,等.老年2型糖尿病患者下肢深静脉血栓形成的相关危险因素[J].中国老年学杂志,2011,31(15):2817~2820.
2017, Vol. 23 
冀公网安备13080202000677号